On Tuesday, ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) opened higher 6.14% from the last session, before settling in for the closing price of $0.38. Price fluctuations for IPA have ranged from $0.27 to $1.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 17.44%. Company’s average yearly earnings per share was noted 63.23% at the time writing. With a float of $20.05 million, this company’s outstanding shares have now reached $30.29 million.
Let’s determine the extent of company efficiency that accounts for 101 employees. In terms of profitability, gross margin is 50.27%, operating margin of -55.48%, and the pretax margin is -125.12%.
ImmunoPrecise Antibodies Ltd (IPA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ImmunoPrecise Antibodies Ltd is 19.60%, while institutional ownership is 7.75%.
ImmunoPrecise Antibodies Ltd (IPA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 63.23% per share during the next fiscal year.
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) Trading Performance Indicators
Check out the current performance indicators for ImmunoPrecise Antibodies Ltd (IPA). In the past quarter, the stock posted a quick ratio of 0.85. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.13 in one year’s time.
Technical Analysis of ImmunoPrecise Antibodies Ltd (IPA)
Looking closely at ImmunoPrecise Antibodies Ltd (NASDAQ: IPA), its last 5-days average volume was 0.64 million, which is a drop from its year-to-date volume of 9.27 million. As of the previous 9 days, the stock’s Stochastic %D was 65.75%. Additionally, its Average True Range was 0.06.
During the past 100 days, ImmunoPrecise Antibodies Ltd’s (IPA) raw stochastic average was set at 19.77%, which indicates a significant decrease from 59.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.98% in the past 14 days, which was lower than the 104.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4572, while its 200-day Moving Average is $0.6457. However, in the short run, ImmunoPrecise Antibodies Ltd’s stock first resistance to watch stands at $0.4129. Second resistance stands at $0.4265. The third major resistance level sits at $0.4479. If the price goes on to break the first support level at $0.3779, it is likely to go to the next support level at $0.3565. Now, if the price goes above the second support level, the third support stands at $0.3429.
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) Key Stats
There are currently 31,062K shares outstanding in the company with a market cap of 18.28 million. Presently, the company’s annual sales total 18,160 K according to its annual income of -20,130 K. Last quarter, the company’s sales amounted to 4,490 K and its income totaled -1,870 K.
